Followers | 258 |
Posts | 19732 |
Boards Moderated | 0 |
Alias Born | 10/03/2004 |

Friday, April 03, 2009 12:42:05 AM
Presently testing--HIV, Rabies, EKC/Herpes. Scheduled or in testing--Ebola, Dengue, Flu/AviFlu.
>>How many do we think are in round two?
In round 2--HIV, Rabies, EKC/Herpes. We think also--Ebola, AviFlu. Ebola may be back in round 1 if the current testing is with a significantly altered version.
>>What's involved in completing a tox package?
Since the drug has never been tried on Humans before, the IND approval will be based entirely on the total results in animal testing. So, since so far test animals haven't shown reactions at therapeutic levels in the histological exams, pretty much increasing the dosage until 1) counter indications occur such as rashes, lesions, weight loss, loss of appetite, etc; and, 2) they begin to die. The test subjects will also be examined for other toxicity factors such as tissue damage, carcinomas, etc. Each test will run about a month plus data evaluation. Could be 1 test or could be 4 or more tests. It all depends on how the nanoviricide is classified. Considering its composition my best guess is it will be classified with monoclonals. That would be a fairly rapid tox workup.
Recent NNVC News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/28/2025 08:36:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2025 04:58:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2024 10:00:49 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2024 09:30:36 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/15/2024 08:44:44 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/27/2024 08:15:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:30:39 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 08/09/2024 08:05:25 PM
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
Wytec Prepares for 1st AI Gunshot Detection Pilot • WYTC • Apr 4, 2025 7:09 AM
ConnectM Receives $1.60 Per Share Buyout Offer from its Three Largest Institutional Investors • CNTM • Apr 2, 2025 9:00 AM
Nightfood Holdings Completes Acquisition of Carryout Supplies, Deepening Vertical Integration in AI-Powered Hospitality Automation • NGTF • Apr 2, 2025 8:30 AM
Avant Technologies Partner, Ainnova, to Sponsor and Present at 2025 Healthcare Innovation Summit in Mexico City • AVAI • Apr 2, 2025 8:00 AM
Glidelogic Corp. Unveils ResearchMind - Pioneering AI-Driven Research Innovation for a Global Academic Community • GDLG • Apr 1, 2025 2:10 PM
Fifty 1 Labs, Inc. Celebrates Groundbreaking SpaceX, NASA, and ISS Yeast Experiment by Subsidiary Genetic Networks • FITY • Apr 1, 2025 9:30 AM